EVP of Diabetes decamps from Sanofi to become Almirall CEO
pharmafile | August 30, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Almirall, Sanofi, biotech, drugs, pharma, pharmaceutical
Sanofi’s Executive Vice President of Diabetes & Cardiocascular, Peter Guenter, has opted to end his 22-year-long stay at the company to become CEO at Almirall. In doing so, he will trade in the pressure of trying to revive Sanofi’s flagging diabetes business to take complete control of Almirall, a company that focuses on dermatological treatments.
The appointment comes after Almirall’s previous CEO the last six years, Eduardo Sanchiz, had decided to step down “to devote more time to his family and other interests”. Sanchiz had been part of the company for 13 years in total and had made significant contribution to the company’s decision to divest its respiratory portfolio to AstraZeneca back in 2014. Guenter will begin his new position on 1 October, following a transition period alongside Sanchiz.
Guenter’s previous experience in the industry encompasses a variety of roles, beginning in sales at SmithKline Belgium before being integrated into Sanofi in 2000 to become General Manager of Belgium operations. From there, he rose to his previously mentioned position in June 2016.
“I am excited and eager to join Almirall as CEO. The company has a clearly defined and sound strategy and has the determination and means to execute this strategy, putting the patients and customers at the centre of everything we do. Together with my team, I am convinced we will be able to fully unlock the value of Almirall”, said Peter Guenter.
“I am particularly satisfied that we have been able to attract Peter Guenter to Almirall. He is a truly global leader and brings a wealth of experience in US, Europe and emerging markets. I am convinced he will bring what is needed to develop Almirall to the next level”, said Jorge Gallardo, Chairman of the Board of Almirall.
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …
Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment …